zenocutuzumab
merus
['solid tumor', 'zenocutuzumab']
zenocutuzumab, a her2-her3 bispecific antibody, successfully targets nrg1 fusions in advanced solid tumors #asco22 #ascodailynews
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.